title: Inefficient cleavage of palmitoyl-protein thioesterase (PPT) substrates by aminothiols: implications for treatment of infantile neuronal ceroid lipofuscinosis.
abstract: Infantile neuronal ceroid lipofuscinosis (INCL, also known as infantile Batten disease) is a devastating neurodegenerative disorder caused by deficiency in the lysosomal enzyme palmitoyl-protein thioesterase (PPT, or CLN1), which functions to remove long-chain fatty acids from cysteine residues in proteins. A previous study suggested that the drug cysteamine, a simple aminothiol used in the treatment of cystinosis, may have utility in the treatment of INCL. In the current study, we compared the catalytic rate constants for the conversion of palmitoyl-CoA (a PPT substrate) and cystine (which accumulates in cystinosis) by cysteamine. We found that while cysteamine can react with palmitoyl-CoA, the rate constant is 10(3)-fold less than the reaction with cystine. Structure-activity studies suggested that it is the thiolate ion that is reactive in the cleavage reaction and that the amino group probably facilitates lysosomal entry. A modest effect of cysteamine (and two related aminothiols, WR 1065 and dimethylaminoethanethiol, DMAET) on PPT substrate accumulation in INCL lymphoblasts was observed. However, at optimum concentration a paradoxical increase in saposin immunoreactivity was seen, indicating possible lysosomal dysfunction. Improvements are needed in the design of small molecules for the treatment of INCL disease.
authors.affiliation: Department of Internal Medicine and Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas, USA.
authors.forename: J-Y
authors.initials: JY
authors.lastname: Lu
authors.forename: S L
authors.initials: SL
authors.lastname: Hofmann
mesh_terms: D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D006801:Humans; D050356:Lipid Metabolism; D008247:Lysosomes / Q000378:metabolism; D008956:Models, Chemical; D009472:Neuronal Ceroid-Lipofuscinoses / Q000628:therapy*; D049231:Saposins / Q000378:metabolism; D013379:Substrate Specificity; D013438:Sulfhydryl Compounds / Q000737:chemistry*; D013869:Thiolester Hydrolases / Q000737:chemistry* / Q000378:metabolism
chemical_list: D049231:Saposins; D013438:Sulfhydryl Compounds; D013869:Thiolester Hydrolases; C095299:palmitoyl-protein thioesterase